Massachusetts General Hospital
2 registered trials on this site, 0 active. This page lists the trials this organization is registered as lead sponsor of, for the compounds covered on PeptideBlog.net. It is a registry listing, not an assessment of the company or its products.
Compounds covered
Registered trials
| Trial | Compound | Phase | Status | Sponsor | Enrolled | Primary completion | Registry updated |
|---|---|---|---|---|---|---|---|
| AT1001 for the Treatment of Long COVID NCT05747534 | Larazotide | Phase 2 | Completed | Massachusetts General Hospital | 107 | Jun 18, 2026 | Aug 18, 2026 |
| AT1001 for the Treatment of COVID-19 Related MIS-C NCT05022303 | Larazotide | Phase 2 | Terminated | Massachusetts General Hospital | 12 | May 15, 2024 | Jun 13, 2024 |
Data: ClinicalTrials.gov, U.S. National Library of Medicine. See the full trial tracker.
